Identification and validation of a seven cuproptosis-associated lncRNA signature to predict the prognosis of endometrial cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Sage Publications Country of Publication: England NLM ID: 0346411 Publication Model: Print Cited Medium: Internet ISSN: 1473-2300 (Electronic) Linking ISSN: 03000605 NLM ISO Abbreviation: J Int Med Res Subsets: MEDLINE
    • Publication Information:
      Publication: Nov. 2012- : London : Sage Publications
      Original Publication: Northampton, Eng., Cambridge Medical Publications ltd.
    • Subject Terms:
      RNA, Long Noncoding*/genetics ; Endometrial Neoplasms*/diagnosis ; Endometrial Neoplasms*/genetics; Humans ; Female ; Prognosis ; CD8-Positive T-Lymphocytes ; Cisplatin ; Tumor Microenvironment/genetics
    • Abstract:
      Objective: Endometrial cancer (EC) is one of the most prevalent cancers in women. Long non-coding RNAs (lncRNAs) are potential diagnostic biomarkers in patients with EC.
      Methods: We obtained clinical information and transcriptome data for 552 patients with EC from The Cancer Genome Atlas database. Cuproptosis-associated lncRNAs were obtained through Pearson's correlation analysis. Univariate and multivariate Cox regression analyses were applied and a signature predicting overall survival (OS) among patients with EC was constructed. We also analyzed the tumor immune microenvironment and drug sensitivity. The results were validated by quantitative real time-polymerase chain reaction, and 5-ethynyl-2'-deoxyuridine and wound-healing assays.
      Results: Seven cuproptosis-associated lncRNAs related to prognosis were screened out and a signature was constructed. OS was significantly superior in the low-risk group. In addition, patients in the low-risk group had more CD8+ T cell infiltration, a stronger type II interferon response, and greater cisplatin sensitivity. Expression levels of some of the lncRNAs were significantly increased by cuproptosis. Furthermore, silencing of lncRNA AC084117.1 significantly inhibited the proliferation and migration of EC cells.
      Conclusion: We constructed a seven cuproptosis-associated lncRNA signature to predict the prognosis of patients with EC with good predictive power.
      Competing Interests: Declaration of conflicting interestsThe authors declare that there is no conflict of interest.
    • References:
      Front Oncol. 2022 Jul 28;12:961213. (PMID: 35965536)
      CA Cancer J Clin. 2019 Jul;69(4):258-279. (PMID: 31074865)
      Lancet. 2016 Mar 12;387(10023):1094-1108. (PMID: 26354523)
      Biol Trace Elem Res. 2020 May;195(1):46-54. (PMID: 31399869)
      Front Mol Biosci. 2022 Mar 04;9:841814. (PMID: 35309510)
      Nat Rev Cancer. 2022 Feb;22(2):102-113. (PMID: 34764459)
      Genes (Basel). 2022 Jul 22;13(8):. (PMID: 35893039)
      Front Mol Biosci. 2021 Aug 24;8:711227. (PMID: 34504870)
      Cell Metab. 2018 Sep 4;28(3):383-399.e9. (PMID: 30043751)
      Front Pharmacol. 2022 Aug 10;13:934396. (PMID: 36034860)
      Drug Resist Updat. 2023 Mar;67:100937. (PMID: 36753923)
      CA Cancer J Clin. 2022 Sep;72(5):409-436. (PMID: 35736631)
      Nat Biotechnol. 2021 Mar;39(3):357-367. (PMID: 33077961)
      Genes Dev. 2011 Sep 15;25(18):1915-27. (PMID: 21890647)
      Semin Cell Dev Biol. 2020 Feb;98:34-43. (PMID: 31100352)
      Front Genet. 2022 Jul 22;13:947551. (PMID: 35938003)
      J Clin Oncol. 2006 Jan 1;24(1):36-44. (PMID: 16330675)
      J Clin Oncol. 2004 Oct 1;22(19):3902-8. (PMID: 15459211)
      CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
      Annu Rev Biomed Eng. 2017 Jun 21;19:163-194. (PMID: 28301735)
      Nat Rev Cancer. 2021 Jul;21(7):446-460. (PMID: 33953369)
      Nat Rev Drug Discov. 2021 Aug;20(8):629-651. (PMID: 34145432)
      Trends Immunol. 2015 Nov;36(11):725-737. (PMID: 26604042)
      Noncoding RNA. 2022 Dec 22;9(1):. (PMID: 36649030)
      Curr Med Res Opin. 2022 Nov;38(11):1935-1945. (PMID: 35975577)
      Front Immunol. 2022 Jul 29;13:934221. (PMID: 35967425)
      J Oncol. 2022 Jul 6;2022:8489387. (PMID: 35847354)
      Anticancer Agents Med Chem. 2023;23(2):210-221. (PMID: 35570522)
      Nat Rev Immunol. 2021 Nov;21(11):718-738. (PMID: 33981085)
      Nat Rev Drug Discov. 2022 Apr;21(4):255-256. (PMID: 35064241)
      Front Genet. 2022 Jul 15;13:938259. (PMID: 35910212)
      J Immunol Res. 2022 Jul 28;2022:4954457. (PMID: 35942212)
      Science. 2022 Mar 18;375(6586):1254-1261. (PMID: 35298263)
      Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109. (PMID: 11900986)
      CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
      Front Immunol. 2022 Jul 29;13:919231. (PMID: 35967366)
      Front Genet. 2022 Jul 22;13:959456. (PMID: 35938036)
      Sci Rep. 2022 Jul 5;12(1):11325. (PMID: 35790864)
      Nat Rev Mol Cell Biol. 2021 Feb;22(2):96-118. (PMID: 33353982)
      Cell Commun Signal. 2019 Aug 20;17(1):99. (PMID: 31429768)
      J Clin Exp Hepatol. 2017 Jun;7(2):152-154. (PMID: 28663680)
      Adv Sci (Weinh). 2023 Sep;10(26):e2300824. (PMID: 37436087)
      Immunity. 2019 Feb 19;50(2):477-492.e8. (PMID: 30737146)
    • Contributed Indexing:
      Keywords: Endometrial cancer; cuproptosis; immune microenvironment; long non-coding RNA; prognosis prediction; survival
    • Accession Number:
      0 (RNA, Long Noncoding)
      Q20Q21Q62J (Cisplatin)
    • Publication Date:
      Date Created: 20231216 Date Completed: 20231218 Latest Revision: 20231219
    • Publication Date:
      20231219
    • Accession Number:
      PMC10725657
    • Accession Number:
      10.1177/03000605231213435
    • Accession Number:
      38102991